Diagnosis and management of astrocytoma: a literature review


  • Dipak Chaulagain Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
  • Volodymyr Smolanka Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine
  • Andriy Smolanka Regional Clinical Center of Neurosurgery and Neurology, Uzhhorod National University, Uzhhorod, Ukraine




astrocytoma, review, diagnosis, extent of resection, surgical management


Astrocytoma is a form of a brain tumor that is rather prevalent. It originates in astrocytes, star-shaped cells that make up the “glue-like” or supporting tissue. Astrocytomas are classified by their nature and severity. According to the World Health Organization, there are I–IV grades of these tumours. Pilocytic astrocytoma, grade II astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme are the most common types of astrocytoma. However, depending on the type, its clinical appearance and diagnosis may change. Similarly, surgical management differs depending on the type of astrocytoma. The current study aims to identify the basic characteristics of different forms of astrocytoma, better understand diagnosis and therapy, and search for publications in NCBI, PubMed, and Google Scholar databases. This article provides an overview of astrocytoma therapy based on its type; the findings greatly depend on different forms of astrocytoma, possibility to perform gross total resection, and lastly, the prognosis. Knowledge of astrocytoma types and manifestations may help in the surgical management of astrocytoma. We also presented a review of the literature on the types and diagnosis of astrocytoma and evaluated current surgical treatments and prognosis.


Download data is not yet available.


Guram K., Smith M., Ginader T., Bodeker K., Pelland D., Pennington E., Buatti J.M. Using smaller-than-standard radiation treatment margins does not change survival outcomes in patients with high-grade gliomas. Pract. Radiat. Oncol. 2019 Jan. 9(1). 16-23. doi: 10.1016/j.prro.2018.06.001.

Kabel A.M., Modais K., Salim A., Ahmad R., Ahmad A., Alnumari K.A. Astrocytoma: insights into risk factors, pathogenesis, diagnosis and management. Journal of Cancer Research and Treatment. 2018. 6(3). 70-73. doi: 10.12691/jcrt-6-3-2.

Moini J., Piran P. Functional and Clinical Neuroanatomy. A Guide for Health Care Professionals. Ch. 1: Histophysiology. Elsevier, 2020. 1-49.

Kapoor M., Gupta V. Astrocytoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021 Jan.

Moini J., Avgeropoulos N.G., Samsam M. Epidemiology of Brain and Spinal Tumours. Ch. 6: Astrocytoma. Elsevier Private Limited, 2021.

Hirtz A., Rech F., Dubois-Pot-Schneider H., Dumond H. Astrocytoma: a hormone-sensitive tumor? Int. J. Mol. Sci. 2020 Nov 30. 21(23). 9114. doi: 10.3390/ijms21239114.

Bikowska-Opalach B., Szlufik S., Grajkowska W., Jozwiak J. Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers. Histol. Histopathology. 2014. 29(10). 1235-1248.

Grimm S.A., Chamberlain M.C. Anaplastic astrocytoma. CNS Oncol. 2016 Jul. 5(3). 145-57. doi: 10.2217/cns-2016-0002.

Singla C., Gupta S. Grade identification of astrocytoma using image processing: a literature review. Proceedings of 10th INDIACom. 2016. 8229.

Tork C.A., Atkinson C. Oligodendroglioma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021 Jan.

Sukheeja D., Singhvi S., Rai N.N., Midya M. A comparative study of histopathology of astrocytomas with intraoperative cytology with special reference to MIB-1 labelling index. J. Clin. Diagn. Res. 2015 Aug. 9(8). EC01-3. doi: 10.7860/JCDR/2015/12372.6281.

Matyja E., Grajkowska W., Stępień K., Naganska E. Heterogeneity of histopathological presentation of pilocytic astrocytoma — diagnostic pitfalls. A review. Folia Neuropathol. 2016. 54(3). 197-211. doi: 10.5114/fn.2016.62530.

Xia J., Yin B., Liu L., Lu Y., Geng D., Tian W. Imaging features of pilocytic astrocytoma in cerebral ventricles. Clin. Neuroradiol. 2016 Sep. 26(3). 341-6. doi: 10.1007/s00062-015-0370-6.

Roskams T. The role of immunohistochemistry in diagnosis. Clin. Liver Dis. 2002 May. 6(2). 571-89, x. doi: 10.1016/s1089-3261(02)00012-0.

Kristensen B.W., Priesterbach-Ackley L.P., Petersen J.K., Wesseling P. Molecular pathology of tumors of the central nervous system. Ann. Oncol. 2019 Aug 1. 30(8). 1265-1278. doi: 10.1093/annonc/mdz164.

Tian Z., Chen C., Fan Y., Ou X., Wang J., Ma X., Xu J. Glioblastoma and anaplastic astrocytoma: differentiation using MRI texture analysis. Front. Oncol. 2019. 9. 876. doi: 10.3389/fonc.2019.00876.

Alshoabi S.A., Alareqi A.A., Omer A.M., Suliman A.G., Daqqaq T.S. Diffuse astrocytoma and the diagnostic dilemma of an unusual phenotype: a case report. Radiol. Case Rep. 2020 Dec 3. 16(2). 319-326. doi: 10.1016/j.radcr.2020.11.023.

Mubarak F., Naeem A. Imaging and histopathological features of pilocytic astrocytoma involving various locations of central nervous system: series of multiple cases. Journal of Neurophysiology and Neurological Disorders. 2021. 9. 1-7.

Barker C.A., Chang M., Beal K., Chan T.A. Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiol. Oncol. 2014 Nov 5. 48(4). 381-6. doi: 10.2478/raon-2014-0019.

Forst D.A., Nahed B.V., Loeffler J.S., Batchelor T.T. Low-grade gliomas. Oncologist. 2014 Apr. 19(4). 403-13. doi: 10.1634/theoncologist.2013-0345.

Pace A., Villani V., Benincasa D., Di Pasquale A., Carapella C.M., Pompili A. P18.07: palliative sedation for brain tumor patients at the end of life. Neuro Oncol. 2014 Sep. 16(Suppl. 2). ii1-ii112. doi: 10.1093/neuonc/nou174.431.

Walbert T., Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat. Res. 2015. 163. 171-84. doi: 10.1007/978-3-319-12048-5_11.

Narita Y., Chernov M.F., Muragaki Y., Kesari S., McCut-cheon I.E. Chemotherapy of diffuse astrocytoma (WHO grade II) in adults. Intracranial gliomas. Part II: Adjuvant therapy. Programming Neurology Surgery. 2018. 31. 145-151. doi: 10.1159/000467375.

Wang G.W., Li B.M. Efficacy of surgery for the treatment of astrocytoma: a protocol of systematic review and meta-analysis. Medicine (Baltimore). 2020 Jun 5. 99(23). e20485. doi: 10.1097/MD.0000000000020485.

Wahner H.C.W., Träger M., Bender K. et al. Predicting survival in anaplastic astrocytoma patients in a single-center cohort of 108 patients. Radiat. Oncol. 2020. 15. 282. doi: 10.1186/s13014-020-01728-8.

Steidl E., Filipski K., Zeiner P.S., Wagner M., Fokas E., Forster M.T., Ronellenfitsch M.W., Divé I., Steinbach J.P., Harter P.N., Bähr O. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. J. Cancer Res. Clin. Oncol. 2021 Aug. 147(8). 2373-2383. doi: 10.1007/s00432-021-03511-y.

Hervey-Jumper S.L., Berger M.S. Role of surgical resection in low- and high-grade gliomas. Curr. Treat. Options Neurol. 2014 Apr. 16(4). 284. doi: 10.1007/s11940-014-0284-7.

Xia L., Fang C., Chen G., Sun C. Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis. BMC Cancer. 2018 Jan 6. 18(1). 48. doi: 10.1186/s12885-017-3909-x.

Patel S.H., Bansal A.G., Young E.B., Batchala P.P., Patrie J.T., Lopes M.B., Jain R., Fadul C.E., Schiff D. Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype. AJNR. 2019 Jul. 40(7). 1149-1155. doi: 10.3174/ajnr.A6102.

Wang L., Liang B., Li Y.I. et al. What is the advance of extent of resection in glioblastoma surgical treatment — a systematic review. Chin. Neurosurg. J. 2019. 5. 2. doi: 10.1186/s41016-018-0150-7.

Choi J., Kim S.H., Ahn S.S. et al. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Sci. Rep. 2020. 10. 2086. doi: 10.1038/s41598-020-59089-x.

Laurent D., Freedman R., Cope L., Sacks P., Abbatematteo J., Kubilis P., Bova F., Rahman M. Impact of extent of resection on incidence of postoperative complications in patients with glioblastoma. Neurosurgery. 2020 May 1. 86(5). 625-630. doi: 10.1093/neuros/nyz313.

Mao H., Li X., Mao W. Advantages of gross total resection in patients with astrocytoma: a population-based study. Oncol. Lett. 2020 Jun. 19(6). 3761-3774. doi: 10.3892/ol.2020.11514.

Karschnia P., Vogelbaum M.A., van den Bent M., Cahill D.P., Bello L., Narita Y., Berger M.S., Weller M., Tonn J.C. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur. J. Cancer. 2021 May. 149. 23-33. doi: 10.1016/j.ejca.2021.03.002.

Motomura K., Chalise L., Ohka F., Aoki K., Tanahashi K., Hirano M., Nishikawa T., Yamaguchi J., Shimizu H., Wakabayashi ., Saito R. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. J. Neurooncol. 2021 Jun. 153(2). 361-372. doi: 10.1007/s11060-021-03776-w.

Revilla-Pacheco F., Rodríguez-Salgado P., Barrera-Ramírez M., Morales-Ruiz M.P., Loyo-Varela M., Rubalcava-Ortega J., Herrada-Pineda T. Extent of resection and survival in patients with glioblastoma multiforme: systematic review and meta-analysis. Medicine (Baltimore). 2021 Jun 25. 100(25). e26432. doi: 10.1097/MD.0000000000026432.




How to Cite

Chaulagain, D., Smolanka, V., & Smolanka, A. (2022). Diagnosis and management of astrocytoma: a literature review. INTERNATIONAL NEUROLOGICAL JOURNAL, 18(1), 23–29. https://doi.org/10.22141/2224-0713.18.1.2022.925



Original Researches

Most read articles by the same author(s)